A clinical trial of an experimental vaccine against Marburg virus has begun in Rwanda, where an outbreak has led to 49 cases ...

Tulisokibart is a tumor necrosis factor (TNF)-like cytokine 1A (TL1A) monoclonal antibody with a different mechanism of ...

In this randomized controlled trial, in patients diagnosed with migraine, it was found that administration of a monoclonal ...

Bristol-Myers Squibb's stock is set to rise with FDA approvals, acquisitions, and a strong oncology portfolio, despite ...

(HealthDay News) — Tulisokibart, a tumor necrosis factor-like cytokine 1A monoclonal antibody, is more effective in inducing clinical remission in patients with moderately to severely active ...

The CDC just released new recommendations for the shot in June 2024, focusing on folks that are 60 or older, who are ...

Monoclonal antibody therapy during childhood vs early adulthood leads to a lower risk for higher disability levels among patients with MS.

Tulisokibart is a tumor necrosis factor–like cytokine 1A (TL1A) monoclonal ... severity. Antibodies to tulisokibart were measured with the use of a high-sensitivity, drug-tolerant assay.

Absci Corporation (NASDAQ:ABSI) is working on developing the use of its biological drug ABS-101 for the treatment of patients with inflammatory bowel disease [IBD]. This drug is already de-risked ...

What is the Center for NextGen Therapeutics? The Center for Nextgen Therapeutics (CNGT) primarily focuses on developing ...

Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...